Wednesday, June 8, 2011

FDA Issues Warning About Benzocaine in Teething Medication

Dr. Clark and our team at Pearland Pediatric Dentistry would like all our parents to know The U.S. Food and Drug Administration, or FDA, has issued a warning about over-the-counter teething pain medicines that contain benzocaine, a local anesthetic and the active ingredient.

The FDA has received reports of methemoglobinemia, a rare but serious blood disorder that is associated with pain relievers, including teething gels, that contain benzocaine sold under the brand names Anbesol, Hurricaine, Orajel, Baby Orajel, Orabase and generic brands.

Methemoglobinemia reduces the amount of oxygen in the blood stream and, in severe cases, can lead to death. Symptoms include pale, gray or blue-colored skin, lips, and nail beds; shortness of breath; fatigue; confusion; headache; lightheadedness; and rapid heart rate. Symptoms could possibly follow a single application of benzocaine with concentrations as low as 7.5 percent.

Read more by checking out this very important announcement. For more information, visit the FDA website and the ADA website.

Or, please call us at Pearland Pediatric Dentistry!

No comments:

Post a Comment